|
1，用于队列研究，病例对照研究和横断面研究的STROBE清单（组合）；2，用于队列研究，病例对照研究和横断面研究的STROBE清单； 3，同类研究清单；4，病例对照研究清单；5，横断面研究清单；6，会议摘要的STROBE清单清单草稿。 STROBE_checklist_case-control STROBE Statement—Checklist of items that
should be included in reports of case-control studies |
| Item No | Recommendation | Title and abstract | 1 | (a)
Indicate the study’s design with a commonly used term in the title or the
abstract | (b)
Provide in the abstract an informative and balanced summary of what was done
and what was found | Introduction | Background/rationale | 2 | Explain the
scientific background and rationale for the investigation being reported | Objectives | 3 | State specific
objectives, including any prespecified hypotheses | Methods | Study design | 4 | Present key
elements of study design early in the paper | Setting | 5 | Describe the
setting, locations, and relevant dates, including periods of recruitment,
exposure, follow-up, and data collection | Participants | 6 | (a) Give
the eligibility criteria, and the sources and methods of case ascertainment
and control selection. Give the rationale for the choice of cases and
controls | (b) For
matched studies, give matching criteria and the number of controls per case | Variables | 7 | Clearly define
all outcomes, exposures, predictors, potential confounders, and effect
modifiers. Give diagnostic criteria, if applicable | Data sources/ measurement | 8* | For each variable of interest, give
sources of data and details of methods of assessment (measurement). Describe
comparability of assessment methods if there is more than one group | Bias | 9 | Describe
any efforts to address potential sources of bias | Study size | 10 | Explain how the
study size was arrived at | Quantitative variables | 11 | Explain how
quantitative variables were handled in the analyses. If applicable, describe
which groupings were chosen and why | Statistical methods | 12 | (a)
Describe all statistical methods, including those used to control for
confounding | (b)
Describe any methods used to examine subgroups and interactions | (c)
Explain how missing data were addressed | (d) If
applicable, explain how matching of cases and controls was addressed | (e)
Describe any sensitivity analyses | Results | Participants | 13* | (a) Report numbers
of individuals at each stage of study—eg numbers potentially eligible,
examined for eligibility, confirmed eligible, included in the study,
completing follow-up, and analysed | (b) Give reasons
for non-participation at each stage | (c) Consider use of a flow diagram | Descriptive data | 14* | (a) Give
characteristics of study participants (eg demographic, clinical, social) and
information on exposures and potential confounders | (b) Indicate
number of participants with missing data for each variable of interest | Outcome data | 15* | Report numbers
in each exposure category, or summary measures of exposure | Main results | 16 | (a) Give
unadjusted estimates and, if applicable, confounder-adjusted estimates and
their precision (eg, 95% confidence interval). Make clear which confounders
were adjusted for and why they were included | (b) Report
category boundaries when continuous variables were categorized | (c) If
relevant, consider translating estimates of relative risk into absolute risk
for a meaningful time period |
Other analyses | 17 | Report other
analyses done—eg analyses of subgroups and interactions, and sensitivity
analyses | Discussion | Key results | 18 | Summarise key
results with reference to study objectives | Limitations | 19 | Discuss
limitations of the study, taking into account sources of potential bias or
imprecision. Discuss both direction and magnitude of any potential bias | Interpretation | 20 | Give a cautious
overall interpretation of results considering objectives, limitations,
multiplicity of analyses, results from similar studies, and other relevant
evidence | Generalisability | 21 | Discuss the
generalisability (external validity) of the study results | Other information | Funding | 22 | Give the source
of funding and the role of the funders for the present study and, if
applicable, for the original study on which the present article is based |
*Give information separately for cases and
controls. Note: An Explanation and Elaboration article
discusses each checklist item and gives methodological background and published
examples of transparent reporting. The STROBE checklist is best used in
conjunction with this article (freely available on the Web sites of PLoS
Medicine at http://www./, Annals of Internal Medicine at
http://www./, and Epidemiology at http://www./).
Information on the STROBE Initiative is available at http://www.strobe-statement.org.
STROBE Statement—Checklist of items that should be included in reports of cohort studies
| Item No | Recommendation | Title and abstract | 1 | (a) Indicate the study’s design with a commonly used term in the title or the abstract | (b) Provide in the abstract an informative and balanced summary of what was done and what was found | Introduction | Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | Objectives | 3 | State specific objectives, including any prespecified hypotheses | Methods | Study design | 4 | Present key elements of study design early in the paper | Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | Participants | 6 | (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up | (b) For matched studies, give matching criteria and number of exposed and unexposed | Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | Data sources/ measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | Bias | 9 | Describe any efforts to address potential sources of bias | Study size | 10 | Explain how the study size was arrived at | Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding | (b) Describe any methods used to examine subgroups and interactions | (c) Explain how missing data were addressed | (d) If applicable, explain how loss to follow-up was addressed | (e) Describe any sensitivity analyses | Results | Participants | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | (b) Give reasons for non-participation at each stage | (c) Consider use of a flow diagram | Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | (b) Indicate number of participants with missing data for each variable of interest | (c) Summarise follow-up time (eg, average and total amount) | Outcome data | 15* | Report numbers of outcome events or summary measures over time | Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | (b) Report category boundaries when continuous variables were categorized | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | Discussion | Key results | 18 | Summarise key results with reference to study objectives | Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | Generalisability | 21 | Discuss the generalisability (external validity) of the study results | Other information | Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based |
*Give information separately for exposed and unexposed groups. Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www./, Annals of Internal Medicine at http://www./, and Epidemiology at http://www./). Information on the STROBE Initiative is available at http://www.strobe-statement.org.
STROBE Statement—checklist of items that should be included in reports of observational studies
| Item No | Recommendation | Title and abstract | 1 | (a) Indicate the study’s design with a commonly used term in the title or the abstract | (b) Provide in the abstract an informative and balanced summary of what was done and what was found | Introduction | Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | Objectives | 3 | State specific objectives, including any prespecified hypotheses | Methods | Study design | 4 | Present key elements of study design early in the paper | Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | Participants | 6 | (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants | (b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed Case-control study—For matched studies, give matching criteria and the number of controls per case | Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | Data sources/ measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | Bias | 9 | Describe any efforts to address potential sources of bias | Study size | 10 | Explain how the study size was arrived at | Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding | (b) Describe any methods used to examine subgroups and interactions | (c) Explain how missing data were addressed | (d) Cohort study—If applicable, explain how loss to follow-up was addressed Case-control study—If applicable, explain how matching of cases and controls was addressed Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy | (e) Describe any sensitivity analyses |
Continued on next page
Results | Participants | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | (b) Give reasons for non-participation at each stage | (c) Consider use of a flow diagram | Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | (b) Indicate number of participants with missing data for each variable of interest | (c) Cohort study—Summarise follow-up time (eg, average and total amount) | Outcome data | 15* | Cohort study—Report numbers of outcome events or summary measures over time | Case-control study—Report numbers in each exposure category, or summary measures of exposure | Cross-sectional study—Report numbers of outcome events or summary measures | Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | (b) Report category boundaries when continuous variables were categorized | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | Discussion | Key results | 18 | Summarise key results with reference to study objectives | Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | Generalisability | 21 | Discuss the generalisability (external validity) of the study results | Other information | Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based |
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies. Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www./, Annals of Internal Medicine at http://www./, and Epidemiology at http://www./). Information on the STROBE Initiative is available at www.strobe-statement.org.
STROBE_checklist_conference_abstract_DRAFT_v03 1 STROBE Statement—Items to be included when reporting observational studies in a conference abstract Item Recommendation Title Indicate the study’s design with a commonly used term in the title (e.g cohort, casecontrol, cross sectional) Authors Contact details for the corresponding author Study design Description of the study design (e.g cohort, case-control, cross sectional) Objective Specific objectives or hypothesis Methods Setting Description of setting, follow-up dates or dates at which the outcome events occurred or at which the outcomes were present, as well as any points or ranges on other time scales for the outcomes (e.g., prevalence at age 18, 1998-2007). Participants Cohort study—Give the most important eligibility criteria, and the most important sources and methods of selection of participants. Describe briefly the methods of follow-up Case-control study—Give the major eligibility criteria, and the major sources and methods of case ascertainment and control selection Cross-sectional study—Give the eligibility criteria, and the major sources and methods of selection of participants Cohort study—For matched studies, give matching and number of exposed and unexposed Case-control study—For matched studies, give matching criteria and the number of controls per case Variables Clearly define primary outcome for this report. Statistical methods Describe statistical methods, including those used to control for confounding Results Participants Report Number of participants at the beginning and end of the study Main results Report estimates of associations. If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period Report appropriate measures of variability and uncertainty (e.g., odds ratios with confidence intervals Conclusions General interpretation of study results
STROBE Statement—Checklist of items that should be included in reports of cross-sectional studies
| Item No | Recommendation | Title and abstract | 1 | (a) Indicate the study’s design with a commonly used term in the title or the abstract | (b) Provide in the abstract an informative and balanced summary of what was done and what was found | Introduction | Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | Objectives | 3 | State specific objectives, including any prespecified hypotheses | Methods | Study design | 4 | Present key elements of study design early in the paper | Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | Participants | 6 | (a) Give the eligibility criteria, and the sources and methods of selection of participants | Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | Data sources/ measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | Bias | 9 | Describe any efforts to address potential sources of bias | Study size | 10 | Explain how the study size was arrived at | Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding | (b) Describe any methods used to examine subgroups and interactions | (c) Explain how missing data were addressed | (d) If applicable, describe analytical methods taking account of sampling strategy | (e) Describe any sensitivity analyses | Results | Participants | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | (b) Give reasons for non-participation at each stage | (c) Consider use of a flow diagram | Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | (b) Indicate number of participants with missing data for each variable of interest | Outcome data | 15* | Report numbers of outcome events or summary measures | Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | (b) Report category boundaries when continuous variables were categorized | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | Discussion | Key results | 18 | Summarise key results with reference to study objectives | Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | Generalisability | 21 | Discuss the generalisability (external validity) of the study results | Other information | Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based |
*Give information separately for exposed and unexposed groups. Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www./, Annals of Internal Medicine at http://www./, and Epidemiology at http://www./). Information on the STROBE Initiative is available at www.strobe-statement.org.
STROBE Statement—checklist of items that should be included in reports of observational studies
| Item No | Recommendation | Title and abstract | 1 | (a) Indicate the study’s design with a commonly used term in the title or the abstract | (b) Provide in the abstract an informative and balanced summary of what was done and what was found | Introduction | Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | Objectives | 3 | State specific objectives, including any prespecified hypotheses | Methods | Study design | 4 | Present key elements of study design early in the paper | Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | Participants | 6 | (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants | (b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed Case-control study—For matched studies, give matching criteria and the number of controls per case | Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | Data sources/ measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | Bias | 9 | Describe any efforts to address potential sources of bias | Study size | 10 | Explain how the study size was arrived at | Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding | (b) Describe any methods used to examine subgroups and interactions | (c) Explain how missing data were addressed | (d) Cohort study—If applicable, explain how loss to follow-up was addressed Case-control study—If applicable, explain how matching of cases and controls was addressed Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy | (e) Describe any sensitivity analyses |
Continued on next page
Results | Participants | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | (b) Give reasons for non-participation at each stage | (c) Consider use of a flow diagram | Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | (b) Indicate number of participants with missing data for each variable of interest | (c) Cohort study—Summarise follow-up time (eg, average and total amount) | Outcome data | 15* | Cohort study—Report numbers of outcome events or summary measures over time | Case-control study—Report numbers in each exposure category, or summary measures of exposure | Cross-sectional study—Report numbers of outcome events or summary measures | Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | (b) Report category boundaries when continuous variables were categorized | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | Discussion | Key results | 18 | Summarise key results with reference to study objectives | Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | Generalisability | 21 | Discuss the generalisability (external validity) of the study results | Other information | Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based |
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies. Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www./, Annals of Internal Medicine at http://www./, and Epidemiology at http://www./). Information on the STROBE Initiative is available at www.strobe-statement.org. STROBE Statement—checklist of items that should be included in reports of observational studies
| Item No. | Recommendation | Page
No. | Relevant text from manuscript | Title and abstract | 1 | (a) Indicate the study’s design with a commonly used term in the title or the abstract |
|
| (b) Provide in the abstract an informative and balanced summary of what was done and what was found |
|
| Introduction |
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported |
|
| Objectives | 3 | State specific objectives, including any prespecified hypotheses |
|
| Methods |
| Study design | 4 | Present key elements of study design early in the paper |
|
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection |
|
| Participants | 6 | (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants |
|
| (b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed Case-control study—For matched studies, give matching criteria and the number of controls per case |
|
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable |
|
| Data sources/ measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group |
|
| Bias | 9 | Describe any efforts to address potential sources of bias |
|
| Study size | 10 | Explain how the study size was arrived at |
|
|
Continued on next page
Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why |
|
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding |
|
| (b) Describe any methods used to examine subgroups and interactions |
|
| (c) Explain how missing data were addressed |
|
| (d) Cohort study—If applicable, explain how loss to follow-up was addressed Case-control study—If applicable, explain how matching of cases and controls was addressed Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy |
|
| (e) Describe any sensitivity analyses |
|
| Results | Participants | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed |
|
| (b) Give reasons for non-participation at each stage |
|
| (c) Consider use of a flow diagram |
|
| Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders |
|
| (b) Indicate number of participants with missing data for each variable of interest |
|
| (c) Cohort study—Summarise follow-up time (eg, average and total amount) |
|
| Outcome data | 15* | Cohort study—Report numbers of outcome events or summary measures over time |
|
| Case-control study—Report numbers in each exposure category, or summary measures of exposure |
|
| Cross-sectional study—Report numbers of outcome events or summary measures |
|
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included |
|
| (b) Report category boundaries when continuous variables were categorized |
|
| (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period |
|
|
Continued on next page
Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses |
|
| Discussion | Key results | 18 | Summarise key results with reference to study objectives |
|
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias |
|
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence |
|
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results |
|
| Other information |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based |
|
|
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies. Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www./, Annals of Internal Medicine at http://www./, and Epidemiology at http://www./). Information on the STROBE Initiative is available at www.strobe-statement.org.
|
